SGLT2 Inhibitors and Heart Failure Post-Chemotherapy

Posted: 2025-04-25 07:09:13 UTC

@JACC JournalsJACCJournals

#SGLT2i

#heartfailure

#anthracycline

#JACCCardioOnc

#CardioOnc

Read With Caution

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Full Thread

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Read With Caution

Verification Details

Status

In Progress

VerifiedPartially VerifiedFalse

Last Updated

2025-04-25 07:09:58 UTC

Verified By

Rollup News

TL;DR;

SGLT2 inhibitors (SGLT2is) may decrease the rate of heart failure hospitalization following anthracycline-containing chemotherapy. This requires further investigation through randomized controlled trials (RCTs).

Key Impact Areas

SGLT2 inhibitors

Heart failure hospitalization

Anthracycline chemotherapy

Cardio-oncology

Challenges

Need for further testing in RCTs to confirm the hypothesis.

SGLT2 Inhibitors and Heart Failure Post-Chemotherapy

Read With Caution

Full Thread

Read With Caution

Verification Details

TL;DR;

Key Impact Areas

Challenges

Claims

Deliberation Map

Similar Rollups